北京
分享至
来源：滚动播报
市场消息： 诺和诺德称Ziltivekimab 相比安慰剂，未能降低主要不良心血管事件（MACE）发生风险。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
